Product Code: GVR-4-68040-504-0
Pet Dewormers Market Summary
The global pet dewormers market size was estimated at USD 2.65 billion in 2025 and is projected to reach USD 5.32 billion by 2033, growing at a CAGR of 9.2% from 2026 to 2033. The market is experiencing growth driven by rising pet ownership, increasing awareness of zoonotic and gastrointestinal parasite risks, and growing adoption of preventive veterinary care.
Enhanced focus on pet health, humanization of pets, and availability of advanced, broad-spectrum deworming products further support market growth. The increasing global burden of parasite-borne diseases is driving demand for pet dewormers, as continuous parasite prevention becomes essential for pet health. According to 2024 Companion Animal Parasite Council (CAPC) data, heartworm prevalence is highest in Mississippi (1 in 15 dogs) and elevated across southern states, while 1 in 200 cats tested positive in high-risk areas such as Texas and Louisiana. Tick-borne diseases, including Lyme disease, affect 1 in 6 dogs in West Virginia, with anaplasmosis impacting 1 in 3 dogs in Maine and Vermont, and ehrlichiosis affecting 1 in 6 dogs in Arkansas. Flea exposure is widespread, affecting 1 in 4 cats and 1 in 7 dogs, making year-round preventive care crucial. The 2025 CAPC forecast highlights the Southeast as a heartworm epicenter, with northward spread along the Mississippi River and Atlantic coast, prompting veterinarians to recommend routine testing and year-round deworming even in traditionally low-risk regions. This has increased demand for broad-spectrum dewormers that combine heartworm, intestinal, and ectoparasite protection, with monthly or long-acting solutions such as Elanco's Credelio Quattro supporting consistent preventive care and market growth.
In addition, tighter regulations on antiparasitic products are reshaping the pet dewormers market by emphasizing safety, resistance management, and veterinarian-led parasite control. For instance, in January 2024 legislation in parts of Europe mandates a physical veterinary examination before dispensing Prescription-Only Medicines-Veterinarian (POM-V), including most flea and worming treatments, limiting unsupervised repeat use and increasing demand for professional consultations. This shift favors premium, broad-spectrum, and combination dewormers that comply with guidelines, supporting higher per-pet expenditure and stable prescription-driven demand. Regulatory alignment with professional bodies such as AAEP and ESCCAP promotes diagnostic testing, record-keeping, and resistance monitoring, enhancing adherence and expanding associated veterinary services. Consequently, the market is moving toward a value- and compliance-focused growth model, ensuring long-term stability while addressing public health and drug-resistance concerns.
Global Pet Dewormers Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pet dewormers market report based on pet, route of administration, dosage form, type, distribution channel, and region.
- Pet Outlook (Revenue, USD Million, 2021 - 2033)
- Dogs
- Cats
- Horses
- Other Pets
- Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
- Oral
- Injectable
- Topical
- Dosage Form Outlook (Revenue, USD Million, 2021 - 2033)
- Solid
- Liquid
- Others
- Type Outlook (Revenue, USD Million, 2021 - 2033)
- OTC
- Prescription
- Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
- Veterinary Hospitals/Clinics
- Retail/Pet Stores
- E-commerce
- Region Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- Europe
- Spain
- Germany
- Portugal
- Romania
- Slovakia
- Czech Republic
- Hungary
- Poland
- Italy
- Ireland
- UK
- France
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
- Latin America
- Middle East & Africa
- South Africa
- UAE
- Saudi Arabia
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Segment Definitions
- 1.2.1. Pet
- 1.2.2. Route of administration
- 1.2.3. Dosage form
- 1.2.4. Type
- 1.2.5. Distribution channel
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
- 1.5. Information/Data Analysis
- 1.5.1. Data Analysis Models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Model 1: Bottom-Up Analysis
- 1.7.2. Model 2: Volume-Pricing Analysis
- 1.7.3. Model 3: Commodity Flow Analysis
- 1.8. List of Secondary Sources
- 1.9. List of Abbreviations
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. Market Variable Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Ancillary/Related Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Awareness and education efforts regarding parasitic worms
- 3.2.1.2. Growing importance of parasite control in pets
- 3.2.1.3. Increasing expert scrutiny
- 3.2.1.4. Increase in zoonotic diseases transfer from pets
- 3.2.1.5. Evolving regulations
- 3.2.1.6. Emergence of new parasitic worms
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Development of drug resistance
- 3.2.2.2. Emergence of unverified treatments
- 3.2.3. Market Opportunity Analysis
- 3.2.4. Market Challenge Analysis
- 3.3. Pricing Analysis
- 3.4. Market Analysis Tools
- 3.4.1. Porter's Five Forces Analysis
- 3.4.2. PESTEL by SWOT Analysis
- 3.5. Estimated Animal Population, by Key Species & Key Countries, 2021-2024
- 3.6. Product Pipeline Analysis
Chapter 4. Pet Dewormers Market: Pet Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Pet Dewormers Market, By Pet Movement Analysis
- 4.3. Pet Dewormers Market Estimates & Forecasts, by Pet, 2021 to 2033 (USD Million)
- 4.4. Dogs
- 4.4.1. Dogs Market Estimates and Forecasts, 2021-2033 (USD Million)
- 4.5. Cats
- 4.5.1. Cats Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6. Horses
- 4.6.1. Horses Market Estimates and Forecasts, 2021-2033 (USD Million)
- 4.7. Other Pets
- 4.7.1. Other Pets Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Pet Dewormers Market: Route of Administration Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Pet Dewormers Market, By Route of Administration Movement Analysis
- 5.3. Pet Dewormers Market Estimates & Forecasts, by Route of Administration, 2021 to 2033 (USD Million)
- 5.4. Oral
- 5.4.1. Oral Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5. Injectable
- 5.5.1. Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.6. Topical
- 5.6.1. Topical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Pet Dewormers Market: By Dosage Form Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Pet Dewormers Market, By Dosage Form Movement Analysis
- 6.3. Pet Dewormers Market Estimates & Forecasts, By Dosage Form, 2021 to 2033 (USD Million)
- 6.3.1. Solid
- 6.3.1.1. Solid Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.2. Liquid
- 6.3.2.1. Liquid Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.3. Others
- 6.3.3.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Pet Dewormers Market: By Type Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. Pet Dewormers Market, By Type Movement Analysis
- 7.3. Pet Dewormers Market Estimates & Forecasts, by Type, 2021 to 2033 (USD Million)
- 7.3.1. OTC
- 7.3.1.1. OTC Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.2. Prescription
- 7.3.2.1. Prescription Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Pet Dewormers Market: By Distribution Channel Estimates & Trend Analysis
- 8.1. Segment Dashboard
- 8.2. Pet Dewormers Market, By Distribution Channel Movement Analysis
- 8.3. Pet Dewormers Market Estimates & Forecasts, by Distribution Channel, 2021 to 2033 (USD Million)
- 8.3.1. Veterinary Hospitals/Clinics
- 8.3.1.1. Veterinary Hospitals/Clinics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.2. Retail/Pet Stores
- 8.3.2.1. Retail/Pet Stores Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.3. E-commerce
- 8.3.3.1. E-commerce Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Pet Dewormers Market: By Regional Estimates & Trend Analysis
- 9.1. Region Market Dashboard
- 9.2. Region Market Share Analysis, 2025 & 2033
- 9.3. North America
- 9.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.3.2. U.S
- 9.3.2.1. Key Country Dynamics
- 9.3.2.2. Competitive Scenario
- 9.3.2.3. Regulatory Framework
- 9.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.3.3. Canada
- 9.3.3.1. Key Country Dynamics
- 9.3.3.2. Competitive Scenario
- 9.3.3.3. Regulatory Framework
- 9.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.3.4. Mexico
- 9.3.4.1. Key Country Dynamics
- 9.3.4.2. Competitive Scenario
- 9.3.4.3. Regulatory Framework
- 9.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4. Europe
- 9.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.2. UK
- 9.4.2.1. Key Country Dynamics
- 9.4.2.2. Competitive Scenario
- 9.4.2.3. Regulatory Framework
- 9.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.3. Germany
- 9.4.3.1. Key Country Dynamics
- 9.4.3.2. Competitive Scenario
- 9.4.3.3. Regulatory Framework
- 9.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.4. France
- 9.4.4.1. Key Country Dynamics
- 9.4.4.2. Competitive Scenario
- 9.4.4.3. Regulatory Framework
- 9.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.5. Italy
- 9.4.5.1. Key Country Dynamics
- 9.4.5.2. Competitive Scenario
- 9.4.5.3. Regulatory Framework
- 9.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.6. Spain
- 9.4.6.1. Key Country Dynamics
- 9.4.6.2. Competitive Scenario
- 9.4.6.3. Regulatory Framework
- 9.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.7. Denmark
- 9.4.7.1. Key Country Dynamics
- 9.4.7.2. Competitive Scenario
- 9.4.7.3. Regulatory Framework
- 9.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.8. Sweden
- 9.4.8.1. Key Country Dynamics
- 9.4.8.2. Competitive Scenario
- 9.4.8.3. Regulatory Framework
- 9.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.9. Norway
- 9.4.9.1. Key Country Dynamics
- 9.4.9.2. Competitive Scenario
- 9.4.9.3. Regulatory Framework
- 9.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.10. Portugal
- 9.4.10.1. Key Country Dynamics
- 9.4.10.2. Competitive Scenario
- 9.4.10.3. Regulatory Framework
- 9.4.10.4. Portugal Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.11. Romania
- 9.4.11.1. Key Country Dynamics
- 9.4.11.2. Competitive Scenario
- 9.4.11.3. Regulatory Framework
- 9.4.11.4. Romania Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.12. Slovakia
- 9.4.12.1. Key Country Dynamics
- 9.4.12.2. Competitive Scenario
- 9.4.12.3. Regulatory Framework
- 9.4.12.4. Slovakia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.13. Czech Republic
- 9.4.13.1. Key Country Dynamics
- 9.4.13.2. Competitive Scenario
- 9.4.13.3. Regulatory Framework
- 9.4.13.4. Czech Republic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.14. Hungary
- 9.4.14.1. Key Country Dynamics
- 9.4.14.2. Competitive Scenario
- 9.4.14.3. Regulatory Framework
- 9.4.14.4. Hungary Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.15. Poland
- 9.4.15.1. Key Country Dynamics
- 9.4.15.2. Competitive Scenario
- 9.4.15.3. Regulatory Framework
- 9.4.15.4. Poland Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.16. Ireland
- 9.4.16.1. Key Country Dynamics
- 9.4.16.2. Competitive Scenario
- 9.4.16.3. Regulatory Framework
- 9.4.16.4. Ireland Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5. Asia Pacific
- 9.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.2. Japan
- 9.5.2.1. Key Country Dynamics
- 9.5.2.2. Competitive Scenario
- 9.5.2.3. Regulatory Framework
- 9.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.3. China
- 9.5.3.1. Key Country Dynamics
- 9.5.3.2. Competitive Scenario
- 9.5.3.3. Regulatory Framework
- 9.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.4. India
- 9.5.4.1. Key Country Dynamics
- 9.5.4.2. Competitive Scenario
- 9.5.4.3. Regulatory Framework
- 9.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.5. Australia
- 9.5.5.1. Key Country Dynamics
- 9.5.5.2. Competitive Scenario
- 9.5.5.3. Regulatory Framework
- 9.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.6. Thailand
- 9.5.6.1. Key Country Dynamics
- 9.5.6.2. Competitive Scenario
- 9.5.6.3. Regulatory Framework
- 9.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.7. South Korea
- 9.5.7.1. Key Country Dynamics
- 9.5.7.2. Competitive Scenario
- 9.5.7.3. Regulatory Framework
- 9.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.6. Latin America
- 9.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.6.2. Brazil
- 9.6.2.1. Key Country Dynamics
- 9.6.2.2. Competitive Scenario
- 9.6.2.3. Regulatory Framework
- 9.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.6.3. Argentina
- 9.6.3.1. Key Country Dynamics
- 9.6.3.2. Competitive Scenario
- 9.6.3.3. Regulatory Framework
- 9.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.7. MEA
- 9.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.7.2. South Africa
- 9.7.2.1. Key Country Dynamics
- 9.7.2.2. Competitive Scenario
- 9.7.2.3. Regulatory Framework
- 9.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.7.3. UAE
- 9.7.3.1. Key Country Dynamics
- 9.7.3.2. Competitive Scenario
- 9.7.3.3. Regulatory Framework
- 9.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.7.4. Saudi Arabia
- 9.7.4.1. Key Country Dynamics
- 9.7.4.2. Competitive Scenario
- 9.7.4.3. Regulatory Framework
- 9.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.7.5. Kuwait
- 9.7.5.1. Key Country Dynamics
- 9.7.5.2. Competitive Scenario
- 9.7.5.3. Regulatory Framework
- 9.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 10. Competitive Landscape
- 10.1. Market Participant Categorization
- 10.1.1. Market Leaders
- 10.1.2. Emerging Players
- 10.2. Market Share/Assessment Analysis, 2025 (Heat Map Analysis)
- 10.3. Company Profiles
- 10.3.1. Zoetis
- 10.3.1.1. Participant's Overview
- 10.3.1.2. Financial Performance
- 10.3.1.3. Product Benchmarking
- 10.3.1.4. Strategic Initiatives
- 10.3.2. Boehringer Ingelheim
- 10.3.2.1. Participant's Overview
- 10.3.2.2. Financial Performance
- 10.3.2.3. Product Benchmarking
- 10.3.2.4. Strategic Initiatives
- 10.3.3. Merck & Co., Inc.
- 10.3.3.1. Participant's Overview
- 10.3.3.2. Financial Performance
- 10.3.3.3. Product Benchmarking
- 10.3.3.4. Strategic Initiatives
- 10.3.4. Elanco Animal Health
- 10.3.4.1. Participant's Overview
- 10.3.4.2. Financial Performance
- 10.3.4.3. Product Benchmarking
- 10.3.4.4. Strategic Initiatives
- 10.3.5. Dechra Pharmaceuticals PLC
- 10.3.5.1. Participant's Overview
- 10.3.5.2. Financial Performance
- 10.3.5.3. Product Benchmarking
- 10.3.5.4. Strategic Initiatives
- 10.3.6. Virbac
- 10.3.6.1. Participant's Overview
- 10.3.6.2. Financial Performance
- 10.3.6.3. Product Benchmarking
- 10.3.6.4. Strategic Initiatives
- 10.3.7. Vetoquinol
- 10.3.7.1. Participant's Overview
- 10.3.7.2. Financial Performance
- 10.3.7.3. Product Benchmarking
- 10.3.7.4. Strategic Initiatives
- 10.3.8. Hester Biosciences Limited
- 10.3.8.1. Participant's Overview
- 10.3.8.2. Financial Performance
- 10.3.8.3. Product Benchmarking
- 10.3.8.4. Strategic Initiatives
- 10.3.9. Ceva Sante Animale
- 10.3.9.1. Participant's Overview
- 10.3.9.2. Financial Performance
- 10.3.9.3. Product Benchmarking
- 10.3.9.4. Strategic Initiatives
- 10.3.10. Intas Pharmaceuticals Ltd.
- 10.3.10.1. Participant's Overview
- 10.3.10.2. Financial Performance
- 10.3.10.3. Product Benchmarking
- 10.3.10.4. Strategic Initiatives
- 10.4. List of other key players